Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
P10746

UPID:
HEM4_HUMAN

ALTERNATIVE NAMES:
Hydroxymethylbilane hydrolyase [cyclizing]; Uroporphyrinogen-III cosynthase

ALTERNATIVE UPACC:
P10746; B2RC13; D3DRF7; Q9H2T1

BACKGROUND:
Uroporphyrinogen-III synthase, also known as Hydroxymethylbilane hydrolyase, is integral to the synthesis of heme, facilitating the conversion of hydroxymethylbilane to uroporphyrinogen III. This step is vital for the subsequent production of heme and other porphyrins, which are key for cellular oxygen transport and various enzymatic reactions.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Uroporphyrinogen-III synthase could open doors to potential therapeutic strategies for treating Congenital erythropoietic porphyria, a genetic disorder resulting from the enzyme's deficiency. This could pave the way for novel treatments that alleviate the disease's photosensitivity and anemia symptoms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.